organization · Reporting owner
Biotest Divestiture Trust
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | 10% owner | June 06, 2019 | June 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date June 06, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,295,580 |
Reported balance
After 2019-06-06 transaction · row 1
1 source rowRow 1 · 2019-06-06 · Sale · Disposed 5,813,954 · Balance 4,295,580 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2019 Filed Jun 7, 2019 20:25 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 5,813,954 | $3.75 | $21,802,327.50 |
DisclosureSEC source: 0001123292-19-000868 · edgar.xml · nonDerivative · entry 1 Biotest Divestiture Trust · CIK 0001748876 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,295,580 Read SEC document |
| May 14, 2018 Filed Aug 9, 2018 20:33 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleNon-Voting Common Stock | 8,591,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-18-000892 · edgar.xml · nonDerivative · entry 1 Biotest Divestiture Trust · CIK 0001748876 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Biotest Pharmaceuticals Corporation Disclosed balance after: 0 F1 · shares: On May 14, 2018, pursuant to a Share Transfer, Amendment and Release Agreement, by and among the issuer, Biotest AG, Biotest Pharmaceuticals Corporation ("BPC"), Biotest US Corporation ("Biotest US"), and The Biotest Devestiture Trust (the "Trust"), BPC transferred to the issuer, for no cash consideration, 8,591,160 shares of the issuer's non-voting common stock previously issued to BPC in June 2017 and representing 100% of the issuer's then-issued and outstanding non-voting common stock. F2 · ownership.nature: Represents securities owned by BPC. BPC is a wholly-owned subsidiary of Biotest US, which is wholly-owned by the Trust. Eric Rosenbach, the trustee of the Trust, is the sole director of each of BPC and Biotest US and has voting and investment discretion with respect to the securities of the issuer held by BPC. Mr. Rosenbach has no pecuniary interest in such securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.